AbbVie gains option to Teneobio BCMA program

By Elizabeth S. Eaton | Feb 11, 2019 | 10:23 PM GMT

AbbVie Inc. (NYSE:ABBV) will pay $90 million up front for an option to acquire bispecific antibody TNB-383B from Teneobio Inc.

Read the full 209 word article

How to gain access

Continue reading with a
two-week free trial.